PLEASANTON, Calif. – March 21, 2017 – NeoTract, Inc., a medical device company focused on addressing unmet needs in the field of urology, announced today that the company’s UroLift System for the treatment of enlarged prostate, or benign prostatic hyperplasia (BPH), was featured in an American Urological Association (AUA) training event that took place last week at the AUA headquarters in Linthicum, Md.
Gregg R. Eure, M.D., F.A.C.S., of Urology of Virginia and Eastern Virginia Medical School, presented an overview of the economics of BPH and conducted simulator training with the UroLift System for 25 East Coast urology residents. The course was co-led by Lori B. Lerner, M.D., of Beth Israel Deaconess Hospital-Plymouth, and Jaspreet S. Sandhu, M.D., of Memorial Sloan Kettering in New York.
“Training the next generation of urologists on the benefits and use of the UroLift System is a great honor,” said Dr, Eure. “I have been treating BPH patients with the UroLift System since March 2015, and have been impressed with the rapid improvement in symptoms and quality of life that has been demonstrated consistently with my own patients and in rigorous clinical studies showing sustained benefits out to four years.”
“The inclusion of the UroLift System in this AUA training event for resident urologists validates the treatment’s place as an important option for patients with BPH,” said Dave Amerson, president and CEO, NeoTract, Inc. “We are excited that enthusiasm about the UroLift System continues to grow amongst both established and new urologists across the United States.”
More than 37 million men in the United States are affected by BPH, which occurs with advancing age when the prostate gland that surrounds the male urethra becomes enlarged and begins to obstruct the urinary system. Symptoms of BPH often include sleepless nights and urinary problems, and can cause loss of productivity, depression and decreased quality of life.
Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra.
About the UroLift System
The FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia and Canada. Learn more at www.UroLift.com.
About NeoTract
NeoTract, Inc. is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. The company’s initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.
# # #
Media Contact:
Nicole Osmer
650.454.0505
nicole@nicoleosmer.com
MAC00417-01 Rev A
